Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data
Main finding · First-time hospitalization for HFResult — go to the resultHazard ratio 1.09 95% CI 0.84–1.42Authors' conclusion
This study showed no significant difference in incident hHF among Black versus White individuals with T2DM following a prescription for empagliflozin.
Study context
- Population
- Adults aged ≥18 years with T2D, Black or White, no previous hospitalization for heart failure (hHF), prescribed empagliflozin between August 2014 and December 2019
- Participants
- 8,789 adults
- Exposure
- Black vs White individuals with T2D prescribed empagliflozin
- Blackn = 3,216
- Whiten = 5,573reference
- Outcome
- Time to first hospitalization for HF after initial empagliflozin prescription
Methodological detailsmulticentre, propensity-score weighted (inverse probability treatment weighting), Cox's cause-specific hazards model
- Multicentre
- Propensity-score weighted (inverse probability treatment weighting)
- Cox's cause-specific hazards model
Main finding
First-time hospitalization for HF
Hazard ratio
1.09
95% CI 0.84–1.42
P = 0.52
Blackvs White
HR 1.09 (95% CI 0.84–1.42); P = 0.52
As reported in the abstract
Observational data: associations, not effects.
Original publication
Comparative analysis of hospitalization risk for incident heart failure in non‐Hispanic Black versus non‐Hispanic White individuals with type 2 diabetes on empagliflozin (Empa‐AA): Insights from real‐world data. Diabetes Obes Metab. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →